Actively Recruiting
Evaluating Intravenous Trontinemab Versus Placebo in Adults Aged 55-80 At Risk for Symptomatic Alzheimers Disease A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Led by Hoffmann-La Roche · Updated on 2026-10-13
1600
Participants Needed
34
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of trontinemab in people aged 55 to 80 who have biological signs of Alzheimers Disease but no current cognitive or functional problems. The study focuses on individuals at risk of progressing to mild cognitive impairment or dementia due to Alzheimers disease, aiming to understand if trontinemab can delay or prevent this progression. Participants will be randomly assigned to receive either intravenous trontinemab or a placebo. The study is designed as a double-blind, parallel-group trial, meaning neither participants nor researchers know who receives the drug or placebo. Treatment and monitoring will continue for up to approximately six years, with regular assessments throughout this period. During the study, participants will undergo various cognitive tests, brain imaging scans, and blood biomarker measurements to track changes in memory, thinking skills, and brain amyloid levels. Researchers will also monitor safety by recording any adverse events or reactions. The main outcome measured is the time it takes for participants to develop symptoms of dementia, with follow-up continuing for up to six years to gather comprehensive data.
CONDITIONS
Brief Title
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
Research Team
R
Reference Study ID Number: WN46072 https://forpatients.roche.com
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here